Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Proof-of-concept trial begins for Vivus's oral PE compounds

Oct. 21, 1999

AnorMed initiates phase III clinical trials in U.S. for Lambda

Oct. 20, 1999

FDA approves Rochester Medical's FemSoft Insert for female stress urinary incontinence

Oct. 5, 1999

New muscarinic antagonists developed at Roche

Oct. 4, 1999

Alpha1A/1L-adrenoceptor agonists disclosed for urinary incontinence, etc.

Oct. 1, 1999

Preclinical study results support potential of NK1 antagonist in treating micturition disorders

Sep. 23, 1999

Ortho-McNeil designs new prostate-selective alpha1a-adrenoceptor antagonists

Sep. 15, 1999

Synaptic and Merck & Co. discontinue development of oral treatment for BPH

Sep. 13, 1999

Wider therapeutic index predicted for Ditropan XL compared to conventional Ditropan

Sep. 10, 1999

NexMed reports progress with topical treatments for sexual dysfunction

Sep. 9, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...